M. Kainer

Significant Impact of Single N-Glycan Residues on the Biological Activity of Fc-based Antibody-like Fragments*

F. Rüker, H. Steinkellner, J. Grass, 2012, The Journal of Biological Chemistry.

Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion

W. Weitzer, T. Bauernhofer, R. Kircheis, 2014 .

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties.

G. Himmler, F. Rüker, B. Antes, 2010, Protein engineering, design & selection : PEDS.

Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.

C. Obinger, F. Rüker, Christoph Hasenhindl, 2013, Protein engineering, design & selection : PEDS.

In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.

F. Rüker, H. Steinkellner, B. Antes, 2014, Biotechnology journal.

Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).

F. Rüker, B. Antes, M. Kainer, 2012, Archives of biochemistry and biophysics.

Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.

Andreas Rizzi, R. Kircheis, O. Szolar, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.